FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Eli Lilly Launches Phase 3 Trial for EloraTZP in Obesity Treatment
研究ライブラリに戻る

Eli Lilly Launches Phase 3 Trial for EloraTZP in Obesity Treatment

November 20, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Eli Lilly Launches Phase 3 Trial for EloraTZP in Obesity Treatment

Eli Lilly and Company has announced a new Phase 3 clinical trial aimed at evaluating the efficacy and safety of a novel peptide therapy called EloraTZP. This study, which is set to begin recruitment soon, will focus on adult participants with obesity who do not have type 2 diabetes. The research, identified by the ClinicalTrials.gov identifier NCT07881432, promises to provide valuable insights into how this innovative treatment could help manage weight in individuals struggling with obesity.

Background

The global obesity epidemic continues to grow, affecting millions of people worldwide and contributing significantly to various health complications. Peptide therapies have emerged as a promising approach for managing obesity due to their ability to target specific biological pathways involved in appetite regulation and metabolism. EloraTZP is a combination therapy that merges two peptides: eloralintide and tirzepatide, both of which are known for their potential in reducing body weight.

Tirzepatide, already under investigation for its benefits in diabetes management, has shown promising results in clinical trials related to obesity. Eloralintide, on the other hand, is a newer compound that targets appetite and satiety mechanisms directly. By combining these two peptides, researchers hope to create a more potent and effective treatment option for people struggling with obesity.

Key Details

The Phase 3 trial will compare the effects of EloraTZP against those of individual components (eloralintide and tirzepatide) as well as placebo treatments. The study is expected to last approximately two years, during which researchers will monitor changes in body weight among participants. This long-term evaluation aims to provide a comprehensive understanding of how these peptides interact when used together and their overall impact on obesity management.

Participants will be carefully selected based on specific criteria, including the absence of type 2 diabetes, to ensure that the study results are as clear and actionable as possible. The trial is sponsored by Eli Lilly and Company, a leading pharmaceutical company with extensive experience in developing innovative treatments for metabolic disorders.

Key Takeaways

  • EloraTZP combines eloralintide and tirzepatide to potentially offer a more effective obesity treatment.
  • The study will assess the safety and efficacy of EloraTZP over two years, providing long-term data on its benefits.
  • Participants must not have type 2 diabetes to ensure clear results focused specifically on obesity management.
  • This research could pave the way for new treatment options in managing weight-related health issues.

What This Means

The launch of this Phase 3 trial represents a significant step forward in the development of peptide therapies for obesity. As researchers continue to explore how these compounds can be used together, we may see more effective and safer treatments become available in the future. For those involved in peptide research or clinical practice, this study offers valuable insights into the potential of combination therapy approaches.

For individuals affected by obesity, the results from this trial could provide hope for new treatment options that address their specific needs without relying on traditional methods that may not be as effective or safe. The broader peptide community will watch closely to see how these findings might influence future research and regulatory decisions regarding similar therapies.

---

Source: ClinicalTrials.gov — Published 2026-11-17

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。